Bracket acquires mProve, both committed to ‘BYOD’ in clinical trials, says CEO

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/oatawa)
(Image: Getty/oatawa)

Related tags: Food and drug administration

“Bring Your Own Device” (BYOD) in clinical trials will be a “critical component” of future research says Bracket CEO following the company’s acquisition of mProve Health.

The clinical trial technology and service provider announced the acquisition of mProve Health​ yesterday. The transaction as supported by the private equity firm and Bracket owner​, Genstar Capital.

mProve has an aggressive technology roadmap and numerous new products and features due to be released in the coming months​,” Jeff Lee, CEO, mProve Health, told Outsourcing-Pharma.com

mProve Health is mobile technology​ provider offering mobile solutions for patient recruitment, patient engagement, and electronic clinical outcome assessments (eCOA).

mProve’s patient engagement tools are a natural complement to our existing eCOA platform. Our first priority will be working with sponsors to bring these two together​,” Jeff Kinell, CEO, Bracket told Outsroucing-Pharma.com.

Moving forward as of now mProve will operate with some independence, he explained. The companies are already working with several sponsor companies on clinical trials together, ​Kinell said.

Bracket and mProve are committed to BYOD,”​ added Kinell. “I think there is a clear consensus from stakeholders that this will be a critical component of research​ in the future​.”

Kinell explained the US Food and Drug Administration (FDA) has been especially receptive to this, ​noting that Lee from mProve has already met with the agency to discuss best practices.

“This investment is a reflection of our belief that this is an important and growing area,​” he added.

Although patient engagement is an emerging area, the data from trials that are leveraging this approach are tremendous. mProve has data showing that patient retention goes up, medication adherence is high, patient compliance with diaries is better, when comprehensive patient engagement programs are put in place​.”

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

Related suppliers

Follow us

Products

View more

Webinars